Clearside Biomedical Bolsa (NASDAQ: CLSD)

Últimas noticias sobre Clearside Biomedical (NASDAQ:CLSD) Bolsa

Clearside Biomedical

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical Inc

Northcoast Research analyst John Healy downgrades Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) from Buy to Neutral.

News

Downgrades

Analyst Ratings

Northcoast Research Downgrades Avis Budget Gr to Neutral

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are racing higher Monday morning following reports that President-elect Donald Trump plans to ease restrictions for <a href="https://www.benzinga.com/topic/self-driving-vehicles-0">self-driving vehicles</a>. 
What To Know: Members of Trump&#8217;s transition team have said they plan to prioritize a federal framework for autonomous vehicles, according to <a href="https://www.bloomberg.com/news/articles/2024-11-17/trump-team-said-to-want-to-ease-us-rules-for-self-driving-cars?embedded-checkout=true">Bloomberg</a>.
The report indicates that the Transportation Department can issue rules through the National Highway Traffic Safety Administration that would make it easier to operate self-driving cars, but a bipartisan piece of legislation from Congress would clear the way for mass adoption. 
Former Uber executive Emil Michael is reportedly one candidate being considered for Transportation secretary. Michael has already spoken with Trump&#8217;s team and potential staffers, according to people familiar with the matter. 
Tesla CEO Elon Musk, who donated to Trump and supported him throughout his campaign, announced plans in October to begin producing the Cybercab robotaxi in 2026. Current regulations pose challenges to Musk&#8217;s plans, including a cap on how many autonomous vehicles can be deployed. 
The National Highway Traffic Safety Administration (NHTSA) currently allows for the deployment of 2,500 self-driving vehicles per year under a granted exemption. Efforts to increase those limits have failed multiple times. The report indicates that a bill for self-driving cars was floated during Trump&#8217;s first term, but did not make it through the Senate. Another attempt at the beginning of the Biden administration failed as manufacturers pushed to include language preventing consumers from forming lawsuits. 
See Also: <a href="https://www.benzinga.com/24/11/42028342/blackwell-backfires-nvidias-ai-chips-struggle-with-server-overheating-impacting-meta-microsoft-and-musks-xai-data-centers">Nvidia&#8217;s Blackwell Chips Are Extra Toasty, Server Overheating Issues Impact Meta, Microsoft And Elon Musk&#8217;s xAI</a>
Last week, Tesla shares moved lower on reports that Trump was planning to get rid of consumer tax credits for EVs. Trump's team is reportedly planning to squash the $7,500 EV tax credit on vehicle purchases as part of a broader tax-reform plan. 
Getting rid of the tax credit could significantly impact the United States'&nbsp;EV&nbsp;transition efforts, but Musk reportedly told Trump's team that he supports putting an end to the EV tax credit. Although it may impact sales in the short term, it will hurt Tesla competitors much more, according to Wedbush analyst&nbsp;Dan Ives.
"We expect Musk to have a big seat at the table as these EV discussions happen within the Trump transition team. We believe any sell-off in Tesla from these reports is the wrong knee-jerk reaction and we would be buyers," Ives said in a note last week.
TSLA Price Action: Tesla shares were up 6.75% at $342.38  at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></li>
</ul>
Photo: courtesy of Tesla.

Movers

TSLA

Tesla Stock Is Trading Higher Monday: What's Going On?

Trading Ideas

FATE

Fate Therapeutics Shares Halted On Circuit Breaker To Upside, Stock Now Up 70.8%

Contracts

Choice Hotels Announces Two SOAR Contracts Supporting Hotel Ownership; Amount Not Disclosed

AILE

iLearningEngines Reports Cybersecurity Incident, CFO Transition, SEC Subpoena, And Financial Restatements; Warns Of Material Impact On Q4 Operations And Ongoing Internal Investigation; Files For Non-Timely 10-Q

Susquehanna analyst James Friedman maintains PagSeguro Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAGS#NYSE">PAGS</a>) with a Positive and lowers the price target from $19 to $16.

Price Target

PAGS

Susquehanna Maintains Positive on PagSeguro Digital, Lowers Price Target to $16

In the current session, the stock is trading at $8.10, after a 0.50% spike. Over the past month, Controladora Vuela Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) stock increased by 13.61%, and in the past year, by 22.13%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1731940235_0.png" alt="Past Year Chart" />

<h3>Comparing Controladora Vuela P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Controladora Vuela has a lower P/E than the aggregate P/E of 15.38 of the Passenger Airlines industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731940235_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

VLRS

P/E Ratio Insights for Controladora Vuela

Susquehanna analyst Christopher Rolland maintains Cirrus Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) with a Positive and raises the price target from $135 to $140.

CRUS

Susquehanna Maintains Positive on Cirrus Logic, Raises Price Target to $140

Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares are trading higher Monday. President-elect Donald Trump selected Liberty Energy CEO and Oklo board member Chris Wright as the next <a href="https://www.benzinga.com/24/11/42024837/trump-taps-liberty-energy-ceo-chris-wright-for-energy-secretary">United States energy secretary</a>.
What Happened: Trump has nominated Wright to lead the U.S. Department of Energy. Wright is the chief of oilfield services company Liberty Energy, and he also serves on Oklo&#8217;s board. 
&#8220;I am deeply honored by this nomination and opportunity to serve our country and continue the mission of bringing affordable, reliable energy to the citizens of the United States and beyond,&#8221; Wright said in a statement.
According to <a href="https://www.cnbc.com/amp/2024/11/16/trump-picks-liberty-energy-ceo-and-oklo-board-member-chris-wright-as-energy-secretary.html">CNBC</a>, Wright will also serve on Trump&#8217;s Council of National Energy. The Liberty Energy CEO is reportedly against the idea that climate change needs to be addressed by moving away from fossil fuels. 
&#8220;There is no climate crisis and we&#8217;re not in the midst of an energy transition either,&#8221; Wright reportedly said in a LinkedIn video posted last year. 
&#8220;There is no such thing as clean energy or dirty energy. All energy sources have impacts on the world both positive and negative.&#8221;
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42036010/alphabet-on-trial-doj-remedies-loom-but-analyst-sees-20-upside-as-discount-to-meta-narrows">Alphabet Braces For DOJ Remedies: Analyst Sees 20% Upside Despite &#8216;Worst Possible&#8217; Risks</a>
Co-founder and CEO of OpenAI Sam Altman also serves on the board of Oklo as chairman. It&#8217;s the only public company that Altman chairs. 
Oklo shares have rallied in recent weeks as hyperscalers increasingly look to nuclear power to meet the rising energy demands of AI data centers. The stock pulled back at the end of last week after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41991912/sam-altman-backed-oklo-reports-q3-earnings-momentum-is-building-every-week">third-quarter financial results</a>.
Oklo reported operating losses of $37.4 million since the start of the year. The company ended the quarter with $288.5 million in cash, cash equivalents and marketable securities.&nbsp;
"We are entering an era of unprecedented energy demand — rivaled perhaps only by initial conversion to electrification over a century ago. The world is now recognizing nuclear&#8217;s role in powering that future," said&nbsp;Jacob DeWitte, co-founder and CEO of Oklo.
"Momentum is building every week — regulators are modernizing, bipartisan support is growing and some of the most influential companies are investing heavily in the space."
OKLO Price Action: <a href="http://benzinga.com/quote/oklo" target="_blank" rel="noreferrer noopener">Oklo shares</a> were up 7.44% at $19.34 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: courtesy of Oklo.

OKLO

Oklo Stock Is Rising Today: What's Driving The Action?

Liberty Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) shares are trading higher premarket on Monday. The company disclosed that the Board of Directors intends to appoint William Kimble as non-executive Chairman and <a href="https://www.benzinga.com/pressreleases/24/11/b42032584/liberty-energy-inc-comments-on-nomination-of-chris-wright-as-u-s-secretary-of-energy-and-announces" target="_blank" rel="noreferrer noopener">Ron Gusek as Chief Executive Officer</a>.
The move came after President-elect Donald J. Trump nominated Liberty&#8217;s Founder, Chairman, CEO, and Director, Chris Wright, for the position of U.S.<a target="_blank" href="https://www.benzinga.com/24/11/42024837/trump-taps-liberty-energy-ceo-chris-wright-for-energy-secretary" rel="noreferrer noopener"> Secretary of Energy</a>.
The new CFO appointment is subject to U.S. Senate confirmation, and Mr. Wright will remain in his current role at Liberty until confirmation is completed.
Wright added, &#8220;Succession planning has been a priority of the Board. Having worked closely with both Bill and Ron, Liberty will be in the safest of hands upon my departure. Ron has been a close partner to me for over two decades and possesses all the criteria to ensure Liberty continues leading the industry in technology innovation and service quality while delivering growth for our valued shareholders.&#8221;
Last week, Trump said that Wright will be a part of the National&nbsp;Energy Council that will be headed by Interior Secretary-designate&nbsp;Doug Burgum, who is currently the governor of North Dakota.
The council&#8217;s main objective will be to cut down regulations and increase <a target="_blank" href="https://www.benzinga.com//node/42024837" rel="noreferrer noopener">investments to boost oil and gas production.</a>
The nomination of Wright, a key player in the fracking industry, signals Trump&#8217;s commitment to boost oil and gas production. The move could potentially lead to increased drilling activities and a greater focus on fracking, despite the U.S. already setting oil production records.
Investors can gain exposure to the stock via&nbsp;SPDR Series Trust SPDR S&amp;P Oil &amp; Gas Equipment &amp; Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XES#NYSE">XES</a>) and Invesco S&amp;P SmallCap Energy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSCE#NASDAQ">PSCE</a>).
Price Action: LBRT shares are up 2.96% at $17.40 premarket at the last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41575181/crude-oil-faces-steepest-one-day-drop-in-over-two-years-energy-stocks-plunge-prices" target="_blank" rel="noreferrer noopener">Crude Oil Faces Steepest One-Day Drop In Over Two Years, Energy Stocks Plunge: Prices&#8217; Are Likely To Remain Under Pressure,&#8217; Analyst Says</a></li>
</ul>

Equities

Large Cap

Management

LBRT

PSCE

SPDR S&P Oil & Gas Equipment & Services ETF

Liberty Energy Names New CEO As Chris Wright Prepares For US Energy Secretary Role

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and maintains $171 price target.

BNTX

Canaccord Genuity Maintains Buy on BioNTech, Maintains $171 Price Target

Keybanc analyst John Vinh maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Overweight and lowers the price target from $1075 to $700.

MPWR

Keybanc Maintains Overweight on Monolithic Power Systems, Lowers Price Target to $700

Stifel analyst Steven Wieczynski maintains Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Buy and raises the price target from $39 to $50.

Stifel Maintains Buy on Viking Holdings, Raises Price Target to $50

Canaccord Genuity analyst George Gianarikas maintains Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) with a Hold and maintains $2.2 price target.

SRFM

Canaccord Genuity Maintains Hold on Surf Air Mobility, Maintains $2.2 Price Target

Stifel analyst Matthew Sheerin initiates coverage on Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy rating and announces Price Target of $28.

Initiation

INGM

Stifel Initiates Coverage On Ingram Micro Holding with Buy Rating, Announces Price Target of $28

SINTX Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares are trading higher by 35% to $2.76 Monday morning after the company announced plans to buy back up to <a href="https://www.benzinga.com/pressreleases/24/11/g42031598/sintx-technologies-announces-stock-repurchase-program">$500K worth of common stock</a> in the upcoming quarters which can reduce the total shares outstanding by approximately 20%.
What Else: In general, a buyback program signals that management may believe the stock is undervalued and has confidence in the company's future performance.
"We believe that the current market undervalues SINTX's potential," said Eric Olson, CEO of SINTX Technologies. "This repurchase program underscores our confidence in the company's strategic initiatives and our commitment to delivering value to our shareholders.&#8221; 
&#8220;By leveraging our strong balance sheet, we are taking a proactive approach to capital allocation, similar to other companies in our industry that have successfully implemented share repurchase programs," Olson concluded.
Read Also: <a href="https://www.benzinga.com/24/11/42032477/spirit-airlines-eyes-financial-stability-with-chapter-11-filing-and-equity-injection">Spirit Airlines Eyes Restructuring With Chapter 11 Filing And Equity Injection</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SINT has a 52-week high of $105.80 and a 52-week low of $2.01.

SINT

Why SINTX Technologies Stock Is Up 50%

Canaccord Genuity analyst Brian McNamara maintains Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) with a Hold and raises the price target from $91 to $94.

Canaccord Genuity Maintains Hold on Spectrum Brands Holdings, Raises Price Target to $94

Stifel analyst Nathan Jones downgrades Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) from Buy to Hold and maintains the price target from $691 to $691.

Stifel Downgrades Parker Hannifin to Hold, Maintains Price Target to $691

Canaccord Genuity analyst Joseph Vafi maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Hold and maintains $205 price target.

GLOB

Canaccord Genuity Maintains Hold on Globant, Maintains $205 Price Target

Stifel analyst Nathan Jones downgrades Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) from Buy to Hold and lowers the price target from $112 to $107.

Stifel Downgrades Ingersoll Rand to Hold, Lowers Price Target to $107

Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Clearside Biomedical (CLSD – Research Report). The associated price...

Buy Rating on Clearside Biomedical: Promising ODYSSEY Trial Results and Undervalued Market Position

Needham analyst Serge Belanger has maintained their bullish stance on CLSD stock, giving a Buy rating today. Serge Belanger has given his Buy ratin...

Buy Rating Affirmed with Increased Price Target for Clearside Biomedical Post-ODYSSEY Trial Success

Clearside stock falls 12% amid Phase 2 data for CLS-AX

Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report) and keeping the price targe...

Clearside Biomedical's CLS-AX Shows Promising Phase 2b Results for Wet AMD, Justifying a Buy Rating with a $6.00 Target

Clearside Biomedical (CLSD) announced that multiple presentations were delivered at the 2024 Annual Meeting of the American Academy of Ophthalmolog...

Clearside Biomedical announces multiple presentations delivered at 2024 AAO

Clearside Biomedical GAAP EPS of -$0.10 beats by $0.02, revenue of $1.03M beats by $0.91M

Reports Q3 revenue $1.04M, consensus $120,000. "We are making outstanding progress advancing our differentiated suprachoroidal delivery pipeline," ...

Clearside Biomedical reports Q3 EPS (10c), consensus (12c)

Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript

Clearside Biomedical Inc ( ($CLSD) ) has released its Q3 earnings. Here is a breakdown of the information Clearside Biomedical Inc presented to its...

Clearside Biomedical Reports Positive Q3 2024 Results

Clearside Biomedical (CLSD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatt...

Promising Outlook for Clearside Biomedical: Buy Rating Backed by Strong Phase 2b ODYSSEY Trial Data and Robust Cash Position

CLSD

Press Releases

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Earnings

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Health Care

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Comments

Clearside Biomedical

Noticias

Últimas noticias sobre Clearside Biomedical (NASDAQ:CLSD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL